Maynard Um
-
-
-
-
-
-
-
Oruka Therapeutics (ORKA) Misses Q1 EPS by 48c
-
-
-
-
-
-
-
Oruka Therapeutics (ORKA) PT Raised to $150 at Stifel
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Oruka Therapeutics (ORKA) Following Data Readout
-
-
-
-
-
-
-
Oruka Therapeutics (ORKA) Misses Q4 EPS by 45c
-
-
-
-
-
-
-
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
-
-
-
-
-
-
Oruka Therapeutics (ORKA) Appoints Laura Sandler as COO
-
417,018 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

